Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note issued to investors on Thursday morning, Benzinga reports. The firm currently has a $30.00 price objective on the stock.

Other equities research analysts have also issued reports about the stock. Wedbush dropped their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Leerink Partners initiated coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Finally, StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Voyager Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $17.43.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $6.75 on Thursday. Voyager Therapeutics has a fifty-two week low of $5.71 and a fifty-two week high of $11.72. The stock has a market cap of $367.16 million, a P/E ratio of -135.00 and a beta of 0.91. The firm’s fifty day moving average price is $6.55 and its 200-day moving average price is $7.61.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. The business had revenue of $29.58 million for the quarter, compared to analyst estimates of $11.52 million. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. During the same period in the prior year, the company earned ($0.51) EPS. Sell-side analysts predict that Voyager Therapeutics will post -1.27 earnings per share for the current year.

Insider Buying and Selling

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now directly owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.53% of the stock is owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

A number of institutional investors have recently added to or reduced their stakes in VYGR. Great Point Partners LLC purchased a new stake in shares of Voyager Therapeutics in the 2nd quarter worth about $12,668,000. Farallon Capital Management LLC boosted its position in shares of Voyager Therapeutics by 77.4% in the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock worth $21,339,000 after purchasing an additional 1,000,000 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after buying an additional 702,030 shares during the last quarter. Armistice Capital LLC grew its stake in shares of Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after buying an additional 528,000 shares during the last quarter. Finally, American Century Companies Inc. increased its position in Voyager Therapeutics by 32.4% during the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock valued at $8,063,000 after buying an additional 249,659 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.